NCT06852144Enrolling by invitation
PET-TC in Thyroid Evaluation
Ruolo Della PET/TC Nella Valutazione di Patologia Tiroidea in un Centro di Medicina Nucleare ad Alto Volume Diagnostico
Source: ClinicalTrials.gov · Last updated 28 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The thyroid gland may have a diffuse or focal uptake of numerous PET/CT radiopharmaceuticals and this may be correlated with underlying benign and malignant thyroid/parathyroid pathologies. It is not clear at present if the uptake of the radiopharmaceutical alone is associated with a potential malignancy of the disease. The aim of the study is to collect evidence and consolidate the diagnostic power of PET/CT, to identify any predictive parameters that can determine whether PET positivity/negativity can in the future avoid unnecessary tests such as needle aspiration.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 418 (estimated)
- First submitted
- 11 Feb 2025
- Start date
- 14 Oct 2024
- Primary completion date
- 30 Apr 2029
- Lead sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Diseases
- Thyroid cancer
- NCT number
- NCT06852144
What you commit to
- Study type: Observational
- Planned participants: 418
- From 14 Oct 2024 to the primary completion date, 30 Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Nothing
Who the study is looking for
- For the retrospective part:
- Patients aged \>18 years,
- Findings of hypercaptant of thyroid/parathyroid relevance to PET/CT or known thyroid or parathyroid pathology and subsequent execution of PET/CT according to normal clinical practice,
- Patients with cytological examination derived from needle aspiration performed no more than 12 months time apart from PET/CT.
- Obtaining informed consent
- For the prospective part:
- Patients aged \>18 years,
- Finding hypercaptant findings of thyroid/parathyroid relevance to PET/CT or known thyroid or parathyroid pathology and subsequent execution of PET/CT according to normal clinical practice.
- Patients scheduled for agesult to be no more than 12 months.
- Obtaining informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuclear medicine, IRCCS, Azienda Ospedalierio-Universitaria di Bologna Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.